CrushSCI.com
208.7平均天数
177.5中位天数
27最短天数
396最长天数
262025发文量

Paper Review Records

全部论文审稿周期

18 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

174 天

Tebapivat: Pharmacokinetic Properties in Preclinical Species and Pharmacodynamic Responses Associated With Pyruvate Kinase Activation in Wild‐Type Mice

作者
Chuck Locuson; Sebastien Ronseaux; Michael McVay展开收起
作者单位
1. Agios Pharmaceuticals, Inc. Cambridge Massachusetts USA; 2. Atavistik Bio Cambridge Massachusetts USA展开收起
PDF源文件 DOI 网页
100 天

Development of a Biorelevant In Vitro Release System and Level A In Vitro‐In Vivo Correlation for Doxorubicin Hydrochloride Liposome Injection via Flow‐Through Cell Method

作者
Xue‐ting Huang; Jing‐jing Liu; Xi‐yang Tang; Guo Yin; Yi Dai; Xiao‐wei Wang展开收起
作者单位
1. College of Pharmacy and International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education Jinan University Guangzhou China; 2. Shenzhen Institute for Drug Control Shenzhen China展开收起
PDF源文件 DOI 网页
176 天

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

作者
Ayaka Tajiri; Shogo Matsumoto; Nanami Furukawa; Kensuke Kagiyama; Hiroshi Ikeda; Kazumasa Fukasawa; Hiroki Takano展开收起
作者单位
1. Drug Discovery Department R&D Division Meiji Seika Pharma Co. Ltd. Tokyo Japan; 2. Yaotsu Breeding Center CLEA Japan, Inc. Gifu Japan; 3. Tokyo Animal and Diet Department CLEA Japan, Inc. Tokyo Japan展开收起
PDF源文件 DOI 网页
257 天

Optimized GFR Estimation Equations for Chinese Neonates and Children: Development of New Models and Comparison With Existing Ones

作者
Hiotong Lam; Yahui Zhang; Zhe Hou; Jinfang Yuan; Zihan Lei; Haiyan Li; Xueting Yao; Tongyan Han; Dongyang Liu展开收起
作者单位
1. Department of Pediatrics Peking University Third Hospital Beijing China; 2. Drug Clinical Trial Center Peking University Third Hospital Beijing China; 3. Department of Pulmonary and Critical Care Medicine Peking University Third Hospital Beijing China; 4. Center of Clinical Medical Research, Institute of Medical Innovation and Research Peking University Third Hospital Beijing China; 5. Department of Cardiology Peking University Third Hospital Beijing China展开收起
PDF源文件 DOI 网页
344 天

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

作者
Siva Nageswara Rao Gajula; Jeevan Sai Kallam; Aarika Kanukolanu; Ganesh Korada; Lakshmi Vineela Nalla展开收起
作者单位
1. Department of Pharmaceutical Analysis GITAM School of Pharmacy GITAM (Deemed to be University) Visakhapatnam Andhra Pradesh India; 2. Multidisciplinary Unit of Research on Translational Initiatives‐Sophisticated Analytical Instrumentation Facility (MURTI‐SAIF) GITAM (Deemed to be University) Visakhapatnam Andhra Pradesh India; 3. Department of Pharmacology GITAM School of Pharmacy GITAM (Deemed to be University) Visakhapatnam Andhra Pradesh India展开收起
PDF源文件 DOI 网页
382 天

Improvement of XZP8257 Dissolution Properties Through Amorphous and Mixed‐Phase Precipitate Formation in Biorelevant Media

作者
Miao Zhang; Shudong Zhang; Bin Wu; Zhe Zhang; Qin Hu; Lin Wang; Dongyang Liu展开收起
作者单位
1. Drug Clinical Trial Center Peking University Third Hospital Beijing China; 2. Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences Northeastern University Boston Massachusetts USA; 3. NMPA Key Laboratory for Research and Evaluation of Generic Drugs Beijing Institute for Drug Control Beijing China展开收起
PDF源文件 DOI 网页

FAQ

BIOPHARMACEUTICS & DRUG DISPOSITION审稿要多久?

截至2026-11-17,CrushSCI 收录了 BIOPHARMACEUTICS & DRUG DISPOSITION 的 18 篇完整审稿记录。最快一篇从收稿到录用用了 27 天(The Role of Nasal Drug Delivery in Migraine Management and Brain‐Targeted Therapy: Insights From Taiwan,2024-12-23 收稿,2025-01-19 录用),最慢一篇用了 396 天;平均 208.7 天,中位数 177.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。